Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Acquires 37,595 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero purchased 37,595 shares of MAIA Biotechnology stock in a transaction on Thursday, September 10th. The stock was acquired at an average cost of $1.32 per share, for a total transaction of $49,625.40. Following the acquisition, the director directly owned 773,296 shares of the company’s stock, valued at approximately $1,020,750.72. This represents a 5.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero acquired 46,620 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $1.35 per share, with a total value of $62,937.00.
• On Thursday, August 27th, Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.39 per share, with a total value of $108,752.21.
• On Wednesday, August 26th, Ramiro Guerrero bought 8,931 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $1.39 per share, for a total transaction of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.33 per share, for a total transaction of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero purchased 11,899 shares of MAIA Biotechnology stock. The shares were bought at an average cost of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Trading Up 4.2%

Shares of NYSEAMERICAN MAIA traded up $0.06 during trading on Monday, reaching $1.35. The company had a trading volume of 122,008 shares, compared to its average volume of 775,572. MAIA Biotechnology, Inc. has a twelve month low of $0.87 and a twelve month high of $3.19. The stock has a 50-day moving average price of $1.35 and a two-hundred day moving average price of $1.39. The stock has a market capitalization of $82.42 million, a PE ratio of -2.19 and a beta of 0.25.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts predict that MAIA Biotechnology, Inc. will post -0.54 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after acquiring an additional 7,746 shares in the last quarter. Marshall Wace LLP acquired a new stake in MAIA Biotechnology in the 2nd quarter valued at $29,000. Jane Street Group LLC purchased a new position in MAIA Biotechnology in the second quarter valued at about $52,000. PVG Asset Management Corp purchased a new position in MAIA Biotechnology in the first quarter valued at about $46,000. Finally, Susquehanna International Group LLP acquired a new position in shares of MAIA Biotechnology during the second quarter worth about $51,000. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.